Technology moves fast, and there’s no better example than the rapid growth of artificial intelligence (AI). Here at Pfizer, we have long been focused on making breakthroughs that change patients’ ...
Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...
TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option NEW ...
LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...
Study met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific ...
At Pfizer, we’re eager to connect with you. Follow Pfizer and our CEO Albert Bourla’s Influencer posts on LinkedIn and Twitter. Get your Pfizer news in small bits by following @Pfizer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results